Serum MACC-1: a new biomarker for breast cancer
Meraj Ahmed, Mohammad Aslam, Meraj Ahmed, Mohammad Aslam
Abstract
Metastasis-associated in colon cancer-1 (MACC-1) is a newly identified tumor marker, found to express in various normal and cancerous tissue. This study is conducted to evaluate the serum MACC-1 level as a diagnostic marker for breast cancer (BC). Sixty new BC patients were included in this study. Patients who received neoadjuvant chemotherapy or with metastatic disease were excluded. Eighty patients of benign disease were taken as control group. All the patients were females with the mean age of 46.7 ± 10.6 years in study group and 40.2 ± 8.4 years in control group (p = 0.0001). The mean serum MACC-1 level in BC patients was 3.46 ± 1.3 ng/ml which was significantly higher than control mean serum MACC-1 level (1.90 ± 0.2 ng/ml) (p < 0.0001). On ROC analysis, the AUC was 0.98 (p ≤ 0.0001; 95% CI = 0.97-1.0) i.e., a good predictor for breast cancer. At the cut-off value of 2.12 ng/ml, the sensitivity and the specificity of serum MACC-1 were 96.7% and 92.5%, respectively. This study showed that serum MACC-1 can be a potential biomarker for diagnosis and tumor progression in patients with breast cancer.
Keywords: MACC-1; breast cancer; new biomarker; serum MACC-1.
Conflict of interest statement
CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.
Copyright: © 2020 Ahmed et al.
Figures
References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. 10.3322/caac.21492.
- Smith RA, Andrews K, Brooks D, DeSantis CE, Fedewa SA, Lortet-Tieulent J, Manassaram-Baptiste D, Brawley OW, Wender RC. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2016; 66:96–114. 10.3322/caac.21336.
- DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. CA Cancer J Clin. 2019; 69:438–451. 10.3322/caac.21583.
- Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol. 2014; 15:e279–e289. 10.1016/S1470-2045(13)70567-9.
- Guidelines WHO Approved by the Guidelines Review Committee. WHO position paper on mammography screening. Geneva: World Health Organization Copyright (c) World Health Organization 2014; 2014 .
- Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25:5287–5312. 10.1200/JCO.2007.14.2364.
- Stein U, Dahlmann M, Walther W. MACC1 - more than metastasis? Facts and predictions about a novel gene. J Mol Med (Berl). 2010; 88:11–18. 10.1007/s00109-009-0537-1.
- Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009; 15:59–67. 10.1038/nm.1889.
- Tan W, Xie X, Li L, Tang H, Ye X, Chen L, Tang W, Gao J, Pan L, Zhang X, Ye F, Li X, Yang L, et al.. Diagnostic and prognostic value of serum MACC1 in breast cancer patients. Oncotarget. 2016; 7:84408–84415. 10.18632/oncotarget.12910.
- Huang Y, Zhang H, Cai J, Fang L, Wu J, Ye C, Zhu X, Li M. Overexpression of MACC1 and Its significance in human Breast Cancer Progression. Cell Biosci. 2013; 3:16. 10.1186/2045-3701-3-16.
Source: PubMed